The influence of nutritional status on the response to HAART in HIV-infected children in South Africa

Pediatric Infectious Disease Journal

Volumn 29, Issue 6, 2010, Pages 511-513

  Naidoo, Reené ^a   Rennert, Wolfgang ^a   Lung, Audrey ^a   Naidoo, Kimesh ^b   McKerrow, Neil ^c  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Africa; Children; HAART; HIV; Malnutrition

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; STAVUDINE; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

AGE; ARTICLE; BODY HEIGHT; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CHILD; CHILD NUTRITION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALNUTRITION; NUTRITIONAL STATUS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOUTH AFRICA; TREATMENT DURATION; UNDERWEIGHT; VIRUS LOAD; ANALYSIS OF VARIANCE; CHI SQUARE DISTRIBUTION; CHILD NUTRITION DISORDERS; COMPLICATION; HIV INFECTIONS; INFANT; PRESCHOOL CHILD; TREATMENT OUTCOME; VIROLOGY;

AGE FACTORS; ANALYSIS OF VARIANCE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHI-SQUARE DISTRIBUTION; CHILD NUTRITION DISORDERS; CHILD, PRESCHOOL; HIV INFECTIONS; HUMANS; INFANT; RETROSPECTIVE STUDIES; SOUTH AFRICA; THINNESS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77953150629     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181d1e989     Document Type: Article

References (25)

1. McKinney R. Growth delay, failure to thrive, and wasting in the HIV-infected child. Sem Pediatr Infect Dis. 1995;6:32-39.
2. McKinney R, Robertson W; Duke Pediatric AIDS Clinical Trials Unit. Effect of human immunodeficiency virus infection on the growth of young children. J Pediatr. 1993;123:579-582.
3. Bailey R, Kamenga M, Nsuami M, et al. Growth of children according to maternal and child HIV, immunological and disease characteristics: a prospective cohort study in Kinshasa, Democratic Republic of Congo. Int J Epidemiol. 1999;28:532-540.
4. World Health Organisation. WHO Case Definitions of HIV for Surveillance and Revised Clinical Staging and Immunological Classification of HIV-related Disease in Adults and Children. Geneva, Switzerland: WHO; 2007.
5. CDC. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years. MMWR Recomm Rep. 2008;57:1-8.
6. Miller T. Nutritional aspects of HIV-infected children receiving highly active antiretroviral therapy. AIDS. 2003;17:S130-S140.
7. Villamor E, Misegades L, Fataki M, et al. Child mortality in relation to HIV infection, nutritional status, and socio-economic background. Int J Epidemiol. 2005;34:61-68.
8. Walker AS, Mulenga V, Sinyinza F, et al. Determinants of survival without antiretroviral therapy after infancy in HIV-1-infected Zambian children in the CHAP trial. J Acquir Immune Defic Syndr. 2006;42:637-645.
9. Gortmaker S, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345:1522-1528.
10. Nachman S, Lindsey J, Moye J, et al. Growth of human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J. 2005;24:352-357.
11. Guillein S, Tomas Ramos J, Resino R, et al. Impact on weight and height with the use of HAART in HIV-infected children. Pediatr Infect Dis J. 2007;26:334-338.
12. Verweel G, van Rossum A, Hartwig N, et al. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. Pediatrics. 2002; 109:E25.
13. van Rossum A, Niesters H, Geelen S, et al. Clinical and virologic response to combination treatment with indinavir, zidovudine, and lamivudine in children with human immunodeficiency virus-1 infection: a multicenter study in The Netherlands. J Pediatr. 2000;136:780-788.
14. Viganò A, Dally L, Bricalli D, et al. Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection. J Pediatr. 1999;135:675-682.
15. Puthanakit T, Oberdorfer A, Akarathum N, et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's national access to antiretroviral program. Clin Infect Dis. 2005;41:100-107.
16. Bolton-Moore C, Mubiana-Mbewe M, Cantrell R, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA. 2007;298:1888-1899.
17. Eley B, Davies MA, Apolles P, et al. Antiretroviral treatment for children. S Afr Med J. 2006;96:988-993.
18. Jaspan H, Berrisford A, Boulle A. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program. Pediatr Infect Dis J. 2008;27:993-998.
19. Reddi A, Leeper S, Grobbler A, et al. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from Kwazulu-Natal, South Africa. BMC Pediatr. 2007;7:13.
20. Adjé-Touré C, Hanson D, Talla-Nzussuo N, et al. Virologic and immunologic response to antiretroviral therapy and predictors of HIV type 1 drug resistance in children receiving treatment in Abidjan, Cote d'Ivoire. AIDS Res Hum Retroviruses. 2008;24:911-917.
21. Essajee S, Kim M, Gonzalez C, et al. Immunologic and virologic responses to HAART in severely immunocompromised HIV-1-infected children. AIDS. 1999;13:2523-2532.
22. World Health Organisation. Antiretroviral Therapy of HIV Infection in Infants and Children: Towards Universal Access. Geneva, Switzerland: WHO; 2006.
23. UNICEF. Progress for Children: A Report Card on Nutrition. New York: UNICEF; 2006.
24. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics. Z Score Data Files. 2000. Available at: www.cdc.gov/ nchs/about/major/nhanes/growthcharts/zscore/zscore. Accessed April 2009.
25. Bandyopadhyay A, Bhattacharyya S. Effect of pre-existing malnutrition on growth parameters in HIV-infected children commencing antiretroviral therapy. Ann Trop Pediatr. 2008;28:279-285.